Search
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate. … Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A).
Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological Chaperones, Heterocyclic Compounds, 1-RingSynonyms: 1-Deoxygalactostatin, 1-DeoxygalactonojirimycinBosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. … Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.
Mixtures: OCUBRAX® SUSPENSION OFTALMICA, OCUBRAX® SUSPENSION OFTALMICACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersZeatin
go.drugbank.com/drugs/DB11337InvestigationalAn aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)
Categories: Heterocyclic Compounds, 2-RingSynonyms: (E)-2-methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol, N6-(4-Hydroxyisopentenyl)adenineElinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigationalElinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsSynonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.Drometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedThe compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia … Despite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as
Mixtures: Garnier Ombrelle Kids Wet N Protect Hypoallergenic SPF 45 Mexoryl Technology, Garnier Ombrelle Kids Wet N Protect Hypoallergenic SPF 45 Mexoryl TechnologyCategories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-RingIsotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574] … Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.
Mixtures: ISOTREXIN JEL, 30 G, ETREXİN % 2 + % 0.05 JELCategories: Retinoids for Topical Use in Acne, Cytochrome P-450 SubstratesHodgkin's Lymphoma
go.drugbank.com/conditions/DBCOND0030382Drugs: Bleomycin · Chlorambucil · Cyclophosphamide · Dacarbazine · Doxorubicin · Gemcitabine +5 moreSynonyms: Hodgkin lymphoma, no ICD-O subtype, Hodgkin lymphoma, no ICD-O subtype (morphologic abnormality)Camphor
go.drugbank.com/drugs/DB01744ApprovedInvestigationalWithdrawnThe FDA ruled that camphorated oil could not be marketed in the United States and that no product could contain a concentration higher than 11%. … [A254252,L43942] However, camphor can be found in several nonprescription medications at lower concentrations.[A254252]
Mixtures: Zam-Buk Ointment, CHAP ICE (R) MEDICATEDSynonyms: D-Camphor, (R)-camphorChronic Myelogenous Leukemia (CML)
go.drugbank.com/conditions/DBCOND0040386Synonyms: Chronic myelogenous leukemia, no ICD-O subtype, Chronic myelogenous leukemia, no ICD-O subtype (morphologic abnormality)